文献速递系统性红斑狼疮

膜性与增殖性狼疮肾炎的结局:单中心30余年随访分析

Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该单中心回顾性队列纳入187例活检证实的狼疮肾炎患者(增殖性135例、膜性38例、混合性14例),随访中位12年、最长42年。膜性狼疮肾炎患者肾存活率显著优于增殖性,但患者总体生存无差异;诊断后1年尿蛋白肌酐比>42 mg/mmol和eGFR<76 ml/min/1.73 m²是进展至终末期肾病的最强预测因素。

要点

  • 膜性狼疮肾炎肾存活率显著优于增殖性,但患者总体生存无差异。
  • 诊断后1年尿蛋白肌酐比>42 mg/mmol和eGFR<76 ml/min/1.73 m²预测终末期肾病。
  • 膜性狼疮肾炎诊断时抗dsDNA抗体更低、C3更高,提示发病机制不同。

核心结论

  • 膜性与增殖性狼疮肾炎在血清学特征和肾存活方面存在显著差异,提示发病机制不同。
  • 诊断后1年肾功能可预测肾存活和患者生存。

研究设计与样本

  • 单中心回顾性观察性研究,纳入活检证实的增殖性、膜性和混合性狼疮肾炎患者。
  • 共187例患者(增殖性135例、膜性38例、混合性14例),随访最长42年,中位12年。

主要发现

  • 膜性狼疮肾炎在非裔加勒比人中的比例高于白人(31% vs 15%,P=0.010)。
  • 膜性狼疮肾炎诊断时抗dsDNA抗体显著更低(P=0.001),C3水平更高(P=0.018)。
  • 增殖性狼疮肾炎5、10、15、20年累积肾存活率分别为91%、81%、75%、66%;膜性分别为100%、97%、92%、84%(P=0.028)。
  • 5、10、15、20年累积患者生存率分别为94%、86%、80%、76%,增殖性与膜性之间无差异。
  • 诊断后1年尿蛋白肌酐比>42 mg/mmol和eGFR<76 ml/min/1.73 m²是进展至终末期肾病的最强预测因素。

临床怎么用

  • 对狼疮肾炎患者应重视诊断后1年的尿蛋白肌酐比和eGFR,用于风险分层。
  • 膜性狼疮肾炎肾预后优于增殖性,但需注意种族差异及长期患者生存。

局限性

  • 单中心回顾性观察性研究,可能存在选择偏倚和信息偏倚。
  • 混合性狼疮肾炎样本量较小(14例),可能影响亚组比较的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare membranous lupus nephritis (MLN) and proliferative lupus nephritis (PLN) with respect to survival, demographic, clinical and laboratory characteristics; and to investigate predictors of renal and patient survival. METHODS: Single-centre retrospective observational study. Patients with biopsy-proven PLN, MLN and mixed lupus nephritis were included. Groups were compared using appropriate statistical tests and survival was analysed through the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of renal and patient survival. RESULTS: A total of 187 patients with biopsy-proven lupus nephritis (135 with PLN, 38 with MLN and 14 with mixed LN) were followed for up to 42 years (median 12 years). There was a higher proportion of MLN amongst Afro-Caribbeans than amongst Caucasians (31% vs 15%, P = 0.010). Patients with MLN had significantly lower anti-dsDNA antibodies (P = 0.001) and higher C3 levels (P = 0.018) at diagnosis. Cumulative renal survival rates at 5, 10, 15 and 20 years were 91, 81, 75 and 66% for PLN and 100, 97, 92 and 84% for MLN, respectively (P = 0.028). Cumulative patient survival at 5, 10, 15 and 20 years was 94, 86, 80 and 76%, with no difference between PLN and MLN. Urinary protein-creatinine ratio above 42 mg/mmol and eGFR below 76 ml/min/1.73 m2, one year after the diagnosis of LN, were the strongest predictors of progression to end-stage renal disease. eGFR below 77 ml/min/1.73 m2, at one year, development of end-stage renal disease and Afro-Caribbean ethnicity were associated with higher mortality. CONCLUSION: Patients with MLN and PLN differ significantly regarding serological profiles and renal survival, suggesting different pathogenesis. Renal function at year one predicts renal and patient survival.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Farinha F, Pepper RJ, Oliveira DG, et al. Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. Rheumatology (Oxford). 2020. PMID: 32303057. doi:10.1093/rheumatology/keaa103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。